Skip to content
Advertisement

FILE - This Feb. 5, 2021, file photo shows the Pfizer logo displayed at the company's headquarters in New York.  Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections. The company announced Friday, Nov. 5,  it will soon ask the U.S. Food and Drug Administration and international regulators to authorize its pill, which is taken twice a day for five days. (AP Photo/Mark Lennihan, File)

FILE - This Feb. 5, 2021, file photo shows the Pfizer logo displayed at the company's headquarters in New York. Pfizer says its experimental pill for COVID-19 cut rates of hospitalization and death by nearly 90% among patients with mild-to-moderate infections. The company announced Friday, Nov. 5, it will soon ask the U.S. Food and Drug Administration and international regulators to authorize its pill, which is taken twice a day for five days. (AP Photo/Mark Lennihan, File)

Featured Photo Galleries